Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells 6,669 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 6,669 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $11.97, for a total transaction of $79,827.93. Following the completion of the sale, the chief executive officer now owns 287,811 shares of the company’s stock, valued at $3,445,097.67. This trade represents a 2.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

KalVista Pharmaceuticals Trading Up 0.2 %

Shares of KALV opened at $12.45 on Thursday. The stock has a market cap of $615.25 million, a P/E ratio of -3.42 and a beta of 0.76. The company has a 50-day moving average of $9.53 and a two-hundred day moving average of $10.27. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50.

Analyst Ratings Changes

Several analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price objective for the company. Finally, Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $23.80.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KALV. Aquatic Capital Management LLC purchased a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth about $44,000. Tower Research Capital LLC TRC grew its holdings in shares of KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 5,502 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 1,494 shares in the last quarter. Martin Worley Group purchased a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth about $86,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after buying an additional 2,043 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).